

Skin Cancer Immunity in Transplant Recipients: Immunosuppressive Medication Impact

Jennifer Scott*

Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA

Abstract

Solid organ transplant recipients are at an increased risk of developing skin cancer due to long-term immunosuppressive medication use. This review explores the complex relationship between immunity, immunosuppressive drugs and the occurrence of Non-Melanoma Skin Cancers (NMSCs) in transplant recipients. We analyze key factors affecting skin cancer risk, including type and dosage of immunosuppressive medications, as well as individual patient characteristics. The literature review suggests that achieving a delicate balance between preventing graft rejection and reducing skin cancer risk is a challenge. We discuss strategies for mitigating NMSC risk, such as the use of alternative immunosuppressive regimens and vigilant dermatological monitoring. Ultimately, a multidisciplinary approach is required to ensure the overall well-being of transplant recipients.

Keywords: Solid organ transplant • Graft rejection • Non-melanoma skin cancer • Immunosuppressive medication • Skin cancer risk • Transplant recipients

Introduction

The transplantation of solid organs has revolutionized modern medicine, offering a lifeline to individuals with end-stage organ failure. These life-saving procedures, however, come with a unique set of challenges. One of the most pressing concerns faced by solid organ transplant recipients is the heightened risk of developing Non-Melanoma Skin Cancers (NMSCs). Immunosuppressive medications, which are a cornerstone of post-transplant management, are essential for preventing graft rejection but also have the paradoxical effect of suppressing the recipient's immune system, rendering them more susceptible to various health issues, including skin cancer. This review delves into the intricate relationship between immunity, immunosuppressive drugs and the development of skin cancer in transplant recipients. As patients navigate the delicate balance between maintaining graft function and mitigating NMSC risk, it becomes imperative to explore the contributing factors, including the type and dosage of immunosuppressive medications, individual patient characteristics and the role of dermatological surveillance in early detection and management [1].

Literature Review

Extensive research has illuminated the considerable risk that solid organ transplant recipients face when it comes to developing NMSCs, a risk substantially higher than that of the general population. The pivotal role of immunosuppressive medications in this heightened risk cannot be overstated. Calcineurin inhibitors such as cyclosporine and tacrolimus, as well as antimetabolites like azathioprine and mycophenolate, serve as the frontline defense against graft rejection. However, they simultaneously compromise the immune system's ability to recognize and combat malignant cells, increasing the risk of skin cancers, particularly NMSCs. Furthermore, the duration and

dosage of immunosuppressive treatment have been linked to the likelihood of NMSC occurrence. Prolonged use and higher doses appear to heighten this risk, necessitating an intricate management approach [2].

The emergence of alternative immunosuppressive regimens has garnered considerable attention within the transplant community. These regimens aim to strike a harmonious balance between preserving graft function and minimizing the patient's risk of skin cancer. Some newer agents, including mammalian target of rapamycin (mTOR) inhibitors, have shown promise in achieving this equilibrium. Their potential to reduce the risk of NMSC while maintaining graft stability is a significant step forward in post-transplant care. Equally crucial is the incorporation of vigilant dermatological monitoring as a standard component of transplant recipient care. Regular skin examinations, when integrated into the post-transplant care regimen, enable the early detection and management of skin cancers, ultimately contributing to improved patient outcomes [3].

Discussion

The discussion section delves into the nuanced complexities of the relationship between immunosuppressive medications and skin cancer risk in transplant recipients. Achieving a balance between preserving graft survival and mitigating the risk of NMSCs is a formidable challenge. Personalized immunosuppressive medication plans, tailored to the individual patient's characteristics and history, are critical in addressing this challenge. Newer agents, such as mTOR inhibitors, provide an encouraging option in this endeavor. These drugs offer the potential to reduce the NMSC risk while still maintaining graft function, presenting a significant advancement in the field [4].

In addition to medication management, vigilant dermatological monitoring is paramount. Transplant teams and dermatologists must collaborate closely to ensure that transplant recipients receive regular skin examinations. Early detection and prompt intervention can significantly impact the course of NMSCs, potentially preventing advanced disease. Additionally, considerations such as the patient's skin phototype and history of UV exposure further complicate the management of NMSC risk. Hence, a comprehensive approach to patient care is essential [5,6].

Conclusion

The heightened risk of non-melanoma skin cancers in solid organ transplant recipients due to immunosuppressive medication use is a multifaceted issue.

*Address for Correspondence: Jennifer Scott, Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA, E-mail: jscott@hotmail.com

Copyright: © 2023 Scott J. This is an open-access article distributed under the terms of the creative commons attribution license which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Received: 04 September, 2023, Manuscript No. jtr-23-117563; **Editor Assigned:** 06 September, 2023, PreQC No. P-117563; **Reviewed:** 18 September, 2023, QC No. Q-117563; **Revised:** 23 September, 2023, Manuscript No. R-117563; **Published:** 30 September, 2023, DOI: 10.37421/2161-0991.2023.13.244

Achieving a delicate equilibrium between preventing graft rejection and minimizing the risk of skin cancer is a formidable task. This necessitates a multidisciplinary approach that integrates personalized immunosuppressive regimens, taking into account individual patient factors and the utilization of promising alternatives like mTOR inhibitors. Equally vital is the incorporation of vigilant dermatological monitoring, serving as a crucial component in early NMSC detection and management. As transplant recipients navigate this intricate landscape, their well-being hinges upon a tailored approach that addresses the intricacies of immunity and skin cancer risk. Continued research and collaboration are essential to refine these strategies and enhance the long-term outcomes of transplant recipients.

Acknowledgement

None.

Conflict of Interest

There are no conflicts of interest by author.

References

1. Cives, Mauro, Francesco Mannavola, Lucia Lospalluti and Maria Chiara Sergi, et al. "Non-melanoma skin cancers: Biological and clinical features." *Int J Mol Sci* 21 (2020): 5394.
2. Coghill, Anna E., Lisa G. Johnson, Dan Berg and Alexa J. Resler, et al. "Immunosuppressive medications and squamous cell skin carcinoma: Nested case-control study within the Skin Cancer after Organ Transplant (SCOT) cohort." *Am J Transplant* 16 (2016): 565-573.
3. Zhao, Honglei, Guobin Shu and Songting Wang. "The risk of non-melanoma skin cancer in HIV-infected patients: New data and meta-analysis." *Int J STD AIDS* 27 (2016): 568-575.
4. Kauffman, H. Myron, Wida S. Cherikh, Yulin Cheng and Douglas W. Hanto, et al. "Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies." *Transplantation* 80 (2005): 883-889.
5. Yanofsky, Valerie R., Hiroshi Mitsui, Diane Felsen and John A. Carucci. "Understanding dendritic cells and their role in cutaneous carcinoma and cancer immunotherapy." *Clin Dev Immunol* 2013 (2013).
6. Bostanci, Seher, Pelin Kocyigit, AyŞegül Alp and Cengizhan Erdem, et al. "Treatment of basal cell carcinoma located in the head and neck region with intralesional interferon α -2a: Evaluation of long-term follow-up results." *Clinical drug investigation* 25 (2005): 661-667.

How to cite this article: Scott, Jennifer. "Skin Cancer Immunity in Transplant Recipients: Immunosuppressive Medication Impact." *J Transplant Technol Res* 13 (2023): 244.